Empagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), is a novel diabetic medication that reduces the risk of progression of chronic kidney dise…

Non-diabetic Chronic Kidney Disease

~Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT07060417

Phase 2

Accelerating Breakthrough Targeted New Therapies for Cardio-Renal Complications in People With T1D (Precision T1D Platform)

Breakthrough T1D has awarded support for a joint University of Michigan-Oregon Health \& Science University Center of Excellence (CoE) to address cardio-renal …

Type 1 DiabetesT1D Heart FailureCardio-renal Vascular Function and Failure+1 more

~Estimated

~$10 – $6,250

Oregon Health and Science UniversityNCT07594145